US2022257800A1PendingUtilityA1

Selective delivery molecules and methods of use

Assignee: AVELAS BIOSCIENCES INCPriority: Jan 30, 2013Filed: May 3, 2021Published: Aug 18, 2022
Est. expiryJan 30, 2033(~6.5 yrs left)· nominal 20-yr term from priority
A61K 49/0054A61K 49/0032A61K 47/60A61K 47/12C07K 7/06A61K 47/65A61K 47/64A61K 49/14A61K 49/0056C07K 19/00A61P 35/00
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or tissue retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) cargo moieties (portion D A and D B ).

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A selective delivery molecule having the structure of SDM-44: 
       
         
           
           
               
               
           
         
       
     
     
         2 . A method of delivering Cy5 and Cy7 to a tissue of interest, comprising contacting the tissue of interest with a selective delivery molecule of  claim 1 . 
     
     
         3 . The method of  claim 2 , wherein the tissue of interest is cancerous. 
     
     
         4 . The method of  claim 3 , wherein the cancerous tissue is: breast cancer tissue, colorectal cancer tissue, squamous cell carcinoma tissue, skin cancer tissue, prostate cancer tissue, melanoma tissue, thyroid cancer tissue, ovarian cancer tissue, cancerous lymph node tissue, cervical cancer tissue, lung cancer tissue, pancreatic cancer tissue, head and neck cancer tissue, or esophageal cancer tissue. 
     
     
         5 . The method of  claim 3 , wherein the cancerous tissue is breast cancer tissue. 
     
     
         6 . The method of  claim 3 , wherein the cancerous tissue is colorectal cancer tissue. 
     
     
         7 . The tissue sample of  claim 3 , wherein the cancerous tissue is squamous cell carcinoma tissue. 
     
     
         8 . The tissue sample of  claim 3 , wherein the cancerous tissue is skin cancer tissue. 
     
     
         9 . The tissue sample of  claim 3 , wherein the cancerous tissue is cancerous lymph node tissue. 
     
     
         10 . A method of visualizing a tissue of interest in an individual in need thereof, comprising:
 (a) administering to the individual a selective delivery molecule of  claim 1 ; and   (b) visualizing at least one of Cy5 or Cy7 of the selective delivery molecule.   
     
     
         11 . The method of  claim 10 , wherein the cancerous tissue is: breast cancer tissue, colorectal cancer tissue, squamous cell carcinoma tissue, skin cancer tissue, prostate cancer tissue, melanoma tissue, thyroid cancer tissue, ovarian cancer tissue, cancerous lymph node tissue, cervical cancer tissue, lung cancer tissue, pancreatic cancer tissue, head and neck cancer tissue, or esophageal cancer tissue. 
     
     
         12 . The method of  claim 11 , wherein the cancerous tissue is breast cancer tissue. 
     
     
         13 . The method of  claim 11 , wherein the cancerous tissue is colorectal cancer tissue. 
     
     
         14 . The tissue sample of  claim 11 , wherein the cancerous tissue is squamous cell carcinoma tissue. 
     
     
         15 . The tissue sample of  claim 11 , wherein the cancerous tissue is skin cancer tissue. 
     
     
         16 . The tissue sample of  claim 11 , wherein the cancerous tissue is cancerous lymph node tissue. 
     
     
         17 . The method of  claim 11 , further comprising surgically removing the tissue of interest from the individual. 
     
     
         18 . The method of  claim 17 , further comprising preparing a tissue sample from the removed tissue of interest. 
     
     
         19 . The method of  claim 11 , further comprising staging the cancerous tissue. 
     
     
         20 . The method of  claim 10 , further comprising visualizing Cy5 or Cy7 of the selective delivery molecule by an emission ratio imaging method. 
     
     
         21 . The method of  claim 10 , wherein the tissue of interest is visualized intraoperatively. 
     
     
         22 . The method of  claim 10 , wherein the molecule is administered intravenously. 
     
     
         23 . A tissue sample comprising a selective delivery molecule of  claim 1 . 
     
     
         24 . The tissue sample of  claim 23 , wherein the tissue sample is cancerous. 
     
     
         25 . The tissue sample of  claim 24 , wherein the cancerous tissue is: breast cancer tissue, colorectal cancer tissue, squamous cell carcinoma tissue, skin cancer tissue, prostate cancer tissue, melanoma tissue, thyroid cancer tissue, ovarian cancer tissue, cancerous lymph node tissue, cervical cancer tissue, lung cancer tissue, pancreatic cancer tissue, head and neck cancer tissue, or esophageal cancer tissue. 
     
     
         26 . The tissue sample of  claim 24 , wherein the cancerous tissue is breast cancer tissue. 
     
     
         27 . The method of  claim 24 , wherein the cancerous tissue is colorectal cancer tissue. 
     
     
         28 . The tissue sample of  claim 24 , wherein the cancerous tissue is squamous cell carcinoma tissue. 
     
     
         29 . The tissue sample of  claim 24 , wherein the cancerous tissue is skin cancer tissue. 
     
     
         30 . The tissue sample of  claim 24 , wherein the cancerous tissue is cancerous lymph node tissue.

Join the waitlist — get patent alerts

Track US2022257800A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.